Lineage Cell Therapeutics
LCTX
107 hedge funds and large institutions have $71.2M invested in Lineage Cell Therapeutics in 2019 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 29 increasing their positions, 26 reducing their positions, and 19 closing their positions.
12% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 26
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.45% less ownership
Funds ownership: 43.87% → 43.42% (-0.45%)
7% less call options, than puts
Call options by funds: $40K | Put options by funds: $43K
9% less funds holding
Funds holding: 118 → 107 (-11)
17% less capital invested
Capital invested by funds: $85.9M → $71.2M (-$14.7M)
42% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$1.15M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$386K |
| 3 |
BC
Broadwood Capital
New York
|
+$290K |
| 4 |
NFC
Northeast Financial Consultants
Westport,
Connecticut
|
+$164K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$142K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DWM
Destination Wealth Management
Walnut Creek,
California
|
-$655K |
| 2 |
PCM
Price Capital Management
Lafayette,
Louisiana
|
-$430K |
| 3 |
State Street
Boston,
Massachusetts
|
-$295K |
| 4 |
Swiss National Bank
Zurich,
Switzerland
|
-$274K |
| 5 |
BlackRock
New York
|
-$147K |
LCTX Hedge Fund Activity: Q2 2019 in Review
107 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2019, worth a combined $71.2M — down 17% from $85.9M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of LCTX and 11 opened new positions — a net loss of 8 holders — while 26 trimmed existing stakes and 29 added.
The largest buyer was Nuveen, opening a new position worth an estimated $1.15M. The largest seller was Destination Wealth Management, exiting entirely with an estimated $655K sold.
- 107 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2019, down from 118 in Q1 2019.
- Funds reported $71.2M of Lineage Cell Therapeutics stock for Q2 2019, down 17% quarter-over-quarter.
- 11 funds opened new Lineage Cell Therapeutics positions in Q2 2019 and 19 closed out, a net change of -8 holders.
- The largest Lineage Cell Therapeutics buyer in Q2 2019 was Nuveen, an estimated $1.15M added.
- The largest Lineage Cell Therapeutics seller in Q2 2019 was Destination Wealth Management, an estimated $655K sold.
Based on aggregated 13F filings for Q2 2019.